Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor effects on platelet and coagulation function in NSTE-ACS patients after PCI
ChiCTR2100053229Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of evolocumab in non–ST-segment elevation acute coronary syndrome (NSTE-ACS), unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: Platelet aggregation rate and Blood lipids. Started Nov 2021; status: recruiting.
02
Drugs
evolocumab
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ChiCTR2100053229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053229.